Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis

Ronald Man Lung Yip, FRCP (Edin), FHKCP* and Cheuk Wan Yim, FRCP, FHKCP†

Abstract: Rheumatoid arthritis (RA) is a multisystem disease that affects the joints and various organs, resulting in compromised quality of life and increased mortality. A wide spectrum of treatment options is available for RA. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are the first-line of treatment for RA, whereas tumor necrosis factor α inhibitors are commonly used as a second-line biological disease-modifying antirheumatic drug following inadequate response to csDMARDs. However, remission remains difficult to achieve. No single agent is effective for all patients. It is important to consider patients' comorbidities, perspectives, and preferences when selecting treatment.

Interleukin 6 (IL-6) plays a prominent role in the pathophysiology of RA and is an important therapeutic target for RA. Tocilizumab and sarilumab are approved IL-6 inhibitors, which have demonstrated good efficacy and tolerability as combination therapy or monotherapy in RA patients with inadequate response to csDMARDs or tumor necrosis factor α inhibitors. Apart from alleviating joint symptoms, inducing remission, and reducing structural damage, tocilizumab and sarilumab exhibit additional advantages in alleviating extra-articular symptoms, such as fatigue and morning stiffness, and have positive effect on anemia and glucose metabolism. Additionally, evidence showed that certain patient subgroups, such as those with comorbidities including anemia and diabetes mellitus, those with early RA, those with high baseline IL-6 levels, those at high risk of tuberculosis infection, or those intolerant to methotrexate monotherapy, may benefit from IL-6 inhibition. Given these advantages, tocilizumab and sarilumab can be considered earlier as a rational choice for treating RA in suitable patients. Future clinical investigations will help refine the use of these agents.

Key Words: candidates for IL-6 inhibition, IL-6 inhibitors, rheumatoid arthritis, sarilumab, tocilizumab

Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and multiple deformities in the joints. It is a multisystem disorder affecting various organs.1 Its prevalence increases with age and affects women much more than men. Key disease characteristics include damage and disability of synovial joints leading to functional disability and reduced productivity.2 Sleep disturbance and depression are common in RA patients.3,4 Large cohorts have confirmed RA as an independent risk factor for cardiovascular diseases5 and osteoporosis.6,7 Mortality rates are nearly twice as much for RA patients than the general population.8 Hence, prompt effective treatment should be initiated to reduce inflammation and pain, prevent progressive joint destruction, minimize systemic complications, and restore patients' function.

The pathophysiology of RA is complex. Recent histopathological and immunopathological studies envisage RA as a clinical syndrome with different subsets.8,9 These subsets involve variable dysregulated interactions among helper T cells, B cells, macrophages, and fibroblasts, as well as proinflammatory cytokines, such as interleukin 1 (IL-1), IL-6, IL-10, IL-18, and tumor necrosis factor α (TNF-α). They all lead toward a common pathway in which persistent synovial inflammation and associated damage to the articular cartilage and underlying bone are present.9,10

In the treatment of RA, prompt initiation of disease-modifying antirheumatic drugs (DMARDs) is very important. The RA treatment armamentarium includes conventional synthetic DMARDs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs). Conventional synthetic DMARDs are the mainstay of RA treatment; methotrexate (MTX) is considered the first-line csDMARD in the European League Against Rheumatism and American College of Rheumatology (ACR) guidelines.1,11,12 If there is insufficient response to the initial csDMARD therapy, guidelines recommend to add a bDMARD or a tsDMARD (introduce a bDMARD first).11,12 However, if patient is not suitable for csDMARD cotherapy, guidelines recommend to consider monotherapy with an IL-6 pathway inhibitor or a tsDMARD, which may have some advantages compared with other bDMARDs.12

Among the bDMARDs, TNF-α inhibitors have the longest safety data and are usually the initial choice for patients who require bDMARD therapy.1 However, not all patients respond to TNF-α inhibitor therapy; randomized clinical trials suggest that approximately 30% of patients fail to respond to them.1,13 This led to the use of other bDMARDs that target other pathways for the treatment of RA, such as tocilizumab and sarilumab (IL-6 signaling blockade), abatacept (T-cell costimulation blockade), and rituximab (B-cell depletion).1,14 Although a variety of agents are available for treatment of RA, sustainable remission remains a challenge. No single agent is effective for all patients. Patients' comorbidities, perspectives (such as feeling of fatigue), and preferences (such as ease of use) are important factors to consider when selecting treatment. In this review, we summarize the efficacy and safety of 2 approved IL-6 inhibitors, tocilizumab and sarilumab, in alleviating the articular and extra-articular symptoms of RA and discuss their position in the RA treatment armamentarium.

ROLE OF IL-6 IN HEALTH AND DISEASE

Interleukin 6 is a pleiotropic cytokine that plays an important role in systemic immune defense against pathogens. It is generated in response to external pathogens and induces signaling in a wide range of cells, including B and T lymphocytes, monocytes, neutrophils, macrophages, endothelial cells, and so on.15,16 While
transient expression of IL-6 is essential to activate the immune system in the body, persistent dysregulated activation of IL-6 can do more harm than good and has been shown to be linked to the pathogenesis of various chronic inflammatory diseases and autoimmune diseases including RA. In addition, IL-6 is implicated in the pathogenesis of many clinical manifestations, such as anemia, insulin resistance, fatigue, mood disorders, osteoporosis, and risk for cardiovascular diseases. For example, IL-6 is a major inducer of hepcidin, a key regulator of iron metabolism and mediator of anaemia in inflammation. Because of the central role of IL-6 in the pathogenesis of anaemia and other manifestations in RA, IL-6 blockade is a promising strategy to alleviate these extra-articular symptoms.

Interleukin 6 plays an integral role in the pathophysiology of RA. It is abundantly expressed in the synovium of RA patients, and it induces joint inflammation and damage, cartilage degradation, joint erosion and narrowing, and progression toward chronic inflammation. Interleukin 6 levels correlate with measures of chronic synovitis and the severity of joint destruction. Furthermore, reduction in IL-6 levels has been shown to a better prognostic marker than other cytokines for improvements in clinical outcomes in RA patients. These findings indicate IL-6 as an important therapeutic target for RA.

**IL-6 INHIBITORS IN RHEUMATOID ARTHRITIS**

The prominent role of IL-6 in RA has stimulated the development of inhibitors of IL-6 signaling for RA treatment. Tocilizumab and sarilumab are inhibitors of the membrane-bound and soluble forms of IL-6 receptor α (IL-6Rα) and are approved for the treatment of RA in many countries, including Europe and the United States. Three other IL-6 inhibitors are undergoing investigation in clinical trials for the treatment of RA, clazakizumab and olokizumab, which target IL-6, and ALX-0061, which binds to IL-6R, whereas sirukumab was withdrawn because of concerns with increased mortality.

**Tocilizumab**

**Characteristics**

Key characteristics of tocilizumab are presented in Table 1. Tocilizumab is a recombinant humanized monoclonal immunoglobulin G1 (IgG1) antibody against IL-6Rα with a dissociation constant (Kd) of 2.5 pM. Age, sex, race, and ethnicity had no effects on the pharmacokinetics of tocilizumab. The approved dose in Europe is intravenous (IV) 8 mg/kg every 4 weeks (q4wk). In the United States, the recommended starting dose is 4 mg/kg q4wk, which may be increased to 8 mg/kg q4wk. For the subcutaneous (SC) formulation, the recommended dose in Europe is 162 mg every week. In the United States, the recommended dose is 162 mg q2wk, followed by an increase to 162 mg every week based on clinical response for patients less than 100 kg in weight. For patients at or greater than 100 kg, the recommended dosing is 162 mg every week. The SC formulation is available as a prefilled syringe or autoinjection pen.

**TABLE 1. Key Characteristics of Tocilizumab and Sarilumab**

| Characteristic | Tocilizumab | Sarilumab |
|---------------|-------------|----------|
| **Molecule** | Recombinant humanized monoclonal IgG1 antibody | Human monoclonal IgG1 antibody |
| **Mechanism of action** | Binds to soluble and membrane bound IL-6Rα | Binds to soluble and membrane bound IL-6Rα |
| **Route of administration** | IV or SC | SC |
| **Presentation** | • IV infusion vial | • Prefilled SC syringe |
| | • Prefilled SC syringe | • Buttonless autoinjection pen |
| | • Autoinjection pen with button | |
| **Dosage and frequency** | IV 4 or 8 mg/kg q4wk | 200 mg q2wk, reduce to 150 mg q2wk to manage lab abnormalities |
| | SC 162 mg q2w or weekly | |
| | Increase low starting dose based on clinical response or reduce dosing to manage lab abnormalities | |
| **Storage and stability** | IV—store 2°C–8°C; once removed from refrigeration, use within 24 h | Store 2°C–8°C; once removed from refrigeration, use within 14 d |
| | SC—store 2°C–8°C; once removed from refrigeration, use within 8 h | |
| **Indication** | Active moderate-severe RA in patients with IR to MTX or other csDMARDs, or TNF-α inhibitors | Active moderate-severe RA in patients with IR to MTX or other csDMARDs, or TNF-α inhibitors |
| | • Combination therapy with MTX, other csDMARDs | • Combination therapy with MTX, other csDMARDs |
| | • Monotherapy for patients intolerant or unsuitable for csDMARDs | • Monotherapy for patients intolerant or unsuitable for csDMARDs |
placebo group, based on the 28-joint Disease Activity Score (DAS28) scores \(^{(35,36)}\) (Table 2). In addition, tocilizumab treatment retarded the progression of structural joint damage as compared with placebo. After 52 weeks of treatment, 84% of patients treated with tocilizumab + MTX did not have any progression, as indicated by the total Genant-modified sharp score, compared with 67% of patients treated with placebo + MTX.\(^{(36)}\)

In patients with IR to other csDMARDs (csDMARD-IR), inclusion of tocilizumab to the existing csDMARD treatment, as opposed to placebo, significantly improved ACR20/50/70 responses and DAS28 remission rates \(^{(35,36)}\) (Table 2).

(ii) Combination Therapy in TNF-IR

In the RADIATE study,\(^{(39)}\) the efficacy of tocilizumab + MTX was compared with placebo + MTX in patients with IR to TNF-\(\alpha\) inhibitors (TNF-IR). Both doses of tocilizumab yielded higher ACR 20/50/70 responses and higher DAS28 remission rates compared with placebo (Table 2). Improvement in HAQ-DI score was also greater with tocilizumab than with placebo (Table 2).

(iii) Monotherapy

In the ADACTA study,\(^{(40)}\) tocilizumab monotherapy was compared with adalimumab (a TNF-\(\alpha\) inhibitor) monotherapy in MTX-IR or MTX-intolerant patients. The ACR20/50/70 scores and DAS28 remission rates were superior for tocilizumab compared with adalimumab (Table 2). In other studies where tocilizumab monotherapy was compared with MTX monotherapy in MTX-IR or MTX-naive patients, tocilizumab yielded higher ACR responses and higher remission rates than MTX \(^{(41,42)}\) (Table 2).

In addition, longer-term data of up to 5 years showed durable efficacy with tocilizumab monotherapy or combination therapy in RA patients, with sustained improvements noted with long-term use.\(^{(44-47)}\) The beneficial effects of tocilizumab on disease remission, radiographic outcomes, and physical function maintained even after \(\leq 5\) years’ treatment.\(^{(44-47)}\)

### Tolerability and Safety

Tocilizumab is generally well tolerated and has a good safety profile. Common adverse events (AEs) include infections, neutropenia, and liver enzyme abnormalities. The majority of AEs reported were of mild to moderate intensity. The proportion of patients who discontinued tocilizumab treatment due to any AEs was low (5% in the tocilizumab group vs. 3% in the placebo group).\(^{(26)}\)

Infections were the most frequently reported treatment-emergent AEs, but no cases of tuberculosis (TB) were observed in clinical trials.\(^{(26)}\) The most frequent serious AEs reported with tocilizumab are infections including bacterial pneumonia, cellulitis, urinary tract infection, herpes zoster, and gastroenteritis.\(^{(26)}\) Malignancies are reported with tocilizumab, but the exposure-adjusted incidence is similar between tocilizumab and placebo groups (1.32 events/100 patient year (PY) and 1.37 events/100 PY, respectively).\(^{(26)}\) Some patients may develop antitocilizumab antibodies, and among patients who were tested for it, 1.6% were positive.\(^{(26)}\)

In long-term studies and real-world studies of up to 7 years, no new safety concerns emerged with either tocilizumab monotherapy or combination therapy over the treatment period.\(^{(44)}\)\(^{(47)}\) During long-term tocilizumab treatment, there was no increase in the incidence of AEs, and the safety profile was consistent with the short-term trials and remained stable over time.\(^{(44-49)}\)

### Sarilumab

**Characteristics**

Key characteristics of sarilumab are listed in Table 1. Sarilumab is a fully human monoclonal IgG1 antibody with an affinity for IL-6R\(\alpha\) (\(K_{D} = 62\) pM for monomeric human IL-6R\(\alpha\)) use.
about 20-fold higher than tocilizumab. Age, sex, race, and body weight do not alter the pharmacokinetics of sarilumab. It is not excreted by the renal or hepatic systems, and no dose adjustments are required for patients with impairment in any of these organ systems. Sarilumab is available as a SC formulation in prefilled syringe or buttonless autoinjector pen at a recommended dose of 200 mg q2wk, to be reduced to 150 mg in case of certain lab abnormalities.

Efficacy

Sarilumab is indicated for the treatment of moderate-severe RA in patients with inadequate response or who are intolerable to previous RA treatment, either as combination therapy or in combination with MTX or other csDMARDs. Key efficacy data for sarilumab summarized according to therapy type are presented in Table 3.

(i) Combination Therapy in MTX-IR

The MOBILITY trial enrolled MTX-IRs who were administered 150 or 200 mg sarilumab + MTX or placebo + MTX q2wk. The ACR20 response rates at week 24 were higher for both doses of sarilumab compared with placebo (Table 3). The results were maintained for up to 52 weeks. Improvement in physical function was greater with sarilumab than placebo, as indicated by HAQ-DI scores at week 24 (Table 3). Progression of structural joint damage was significantly retarded with sarilumab compared with placebo by weeks 24 and 52. Among patients who continued in the open-label extension phase of the trial, the observed clinical efficacy (in terms of ACR responses, physical function, remission, and radiographic outcomes) sustained until the end of the 1-year extension period.

In the KAKEHASI trial in Japan, MTX-IRs were randomized to receive sarilumab or placebo, in combination with MTX. The ACR response rates at week 24 were higher for both doses of sarilumab than in the placebo arm, and the response rates remained high at the end of the 52-week study (Table 3). The HAQ-DI scores and DAS28 and CDAI remission rates at week 24 were in favor of sarilumab over placebo (Table 3). These results are consistent with the observations in non-Japanese patients in the MOBILITY trial.

(ii) Combination Therapy in TNF-IR

In the TARGET trial, the efficacy of sarilumab + csDMARDs therapy was compared with placebo + csDMARDs in patients who had inadequate response or were intolerant to 1 or more anti–TNF-α therapy. More patients achieved ACR responses and DAS28 remission by week 24 with sarilumab treatment than with placebo (Table 3). The ACR20 responses were independent of the number of prior anti–TNF-α agents. Physical function, assessed by HAQ-DI score, improved significantly with both doses of sarilumab compared with placebo (Table 3).

(iii) Monotherapy

The MONARCH trial was a head-to-head comparison of sarilumab monotherapy with adalimumab monotherapy in MTX-IR or patients who were intolerant or unsuitable for MTX treatment. The ACR responses and changes in HAQ-DI scores were in favor of sarilumab over adalimumab (Table 3). Compared with the adalimumab arm, more patients in the sarilumab arm achieved DAS28 and CDAI remission (Table 3).

(iv) Switching From Another IL-6 Inhibitor—Tocilizumab

The efficacy of open-label sarilumab + csDMARD treatment in patients previously treated with tocilizumab + csDMARD was evaluated in a post hoc analysis. Among patients who had not responded to 8 mg/kg tocilizumab, a substantial proportion of patients responded to 200 mg sarilumab treatment by week 24. The ACR20/50/70 was achieved in 60%/46%/32% of patients

### TABLE 3. Efficacy of Sarilumab in Key Clinical Trials

| Study Name; Therapy Type; Patient Population | Study Length | Treatment Arms | N   | ACR20/50/70 (%) | DAS28 Change From Baseline | CDAI Score <2.6 (%) | DAS28 Score <2.6 (%) | HAQ-DI Change From Baseline |
|---------------------------------------------|-------------|----------------|-----|----------------|---------------------------|-------------------|--------------------------|---------------------------|
| MOBILITY combination; MTX-IR                | 52 wk       | SAR 200 mg + MTX | 399 | 66.4/46/25     | —                         | 13.8              | 34.1                     | —                         |
|                                             |             | Placebo + MTX   | 398 | 33.4/17/7      | —                         | 5                 | 10.1                     | —                         |
| KAKEHASI combination; MTX-IR               | 52 wk       | SAR 200 mg + MTX | 80  | 57.5/38.8/15   | —                         | 10.0              | 40                       | —                         |
|                                             |             | Placebo + MTX   | 81  | 67.9/43.2/18.5 | —                         | 6.2               | 35.8                     | —                         |
| TARGET combination; MTX-IR or intolerant   | 24 wk       | SAR 200 mg + DMARDs | 184 | 60.9/40.8/16.3 | —                         | 2.8               | 28.8                     | —                         |
|                                             |             | Placebo + csDMARDs | 181 | 55.8/37/19.9  | —                         | 2.4               | 24.9                     | —                         |
| MONARCH combination; MTX-IR or intolerant | 24 wk       | SAR 200 mg      | 184 | 71.7/45.7/23.4 | —                         | 3.28              | 26.6                     | —                         |
|                                             |             | Adalimumab 40 mg | 185 | 58.4/29.7/11.9 | —                         | 2.20              | 7                       | 0.43                      |

*aHAQ-DI results are for week 16; other results are for 24 weeks.*

*bResults shown are for week 24.*

*cHAQ-DI results are for week 12.*
Tolerability and Safety

Sarilumab has demonstrated a good tolerability and safety profile in clinical trials, similar to tocilizumab. Among the AEs that were relatively more frequent with sarilumab (6% and 4% with 200 and 150 mg, respectively) than with placebo (0%), the decrease in absolute neutrophil count was not associated with higher incidence of infections. Liver enzyme abnormalities were observed more often with sarilumab (29% and 27% of patients with elevated aspartate aminotransferase, and 45% and 40% of patients with elevated alanine aminotransferase, respectively) than with placebo (13% of patients with elevated aspartate aminotransferase and 24% of patients with elevated alanine aminotransferase). However, for the majority of the patients, the elevated enzyme levels were ≤ 3 times upper limit of normal.

Anemia

Tocilizumab treatment was associated with reduced fatigue in RA patients, as measured by a consistent increase in mean functional assessment of chronic illness therapy-fatigue scores from baseline to week 96 (increase from baseline 7.3 ± 10.4). Systematic literature review also showed improvements in mood and mental status, and physical and mental quality of life in RA patients treated with tocilizumab.

In phase 3 trials, RA patients receiving sarilumab in combination with MTX or other csDMARDs, or as monotherapy experienced greater relief from pain and fatigue at weeks 24 and 52 when compared with the placebo group or adalimumab group. At 24 weeks, the OR for greater than 30% improvement in visual analog scale for pain was 2.52 (95% CI, 1.62–3.92) and 1.70 (95% CI, 1.12–2.58) for sarilumab versus placebo and adalimumab, respectively. The OR for greater than 30% improvement in functional assessment of chronic illness therapy-fatigue score was 1.90 (95% CI, 1.22–2.94) for sarilumab versus placebo. Overall, pain improved in approximately 50% of the patients and fatigue in 40% of the patients after 52 weeks of treatment with sarilumab.

Patients with RA treated with sarilumab + MTX also showed improvements in mood and quality of life, and mood by week 24 compared with placebo + MTX.

Fasting Glucose and Glycated Hemoglobin

An observational study reported a significant decrease in glycated hemoglobin (HbA1c) values after 3 months (−0.4% from baseline) of initiation of tocilizumab in RA patients. Treatment with TNF-α inhibitors also elicited a decrease in HbA1c, but to a lesser degree (−0.1% from baseline to 3 months).

Subanalysis of RA patients with concomitant diabetes mellitus in the MOBILITY and TARGET trials revealed improvements in glycemic parameters with sarilumab in combination with MTX or other csDMARDs. By week 24, fasting blood glucose (LSM difference, −1.22; 95% CI, −1.64 to −0.80) and HbA1c levels (LSM difference, −0.69; 95% CI, −1.00 to −0.38) decreased significantly in the sarilumab group compared with the placebo group. These effects were independent of changes in body weight, C-reactive protein (CRP) levels, ACR5 responses, or remission status.

In summary, tocilizumab and sarilumab have shown efficacy in alleviating RA symptoms in MTX-IR and TNF-IR. They reduce joint symptoms and structural damage to joints and induce disease remission. Both agents work well in combination with MTX or other csDMARDs and have demonstrated superior efficacy as a monotherapy over adalimumab. These observed clinical benefits persist with long-term use of both agents. It should be noted that IL-6 inhibition can directly decrease the synthesis of CRP by hepatocytes. Therefore, composite outcome measures that include CRP level may be unreliable for disease monitoring in patients treated with IL-6 inhibitors. Nonetheless, other disease activity measure that does not include CRP, such as CDAI, and other clinical outcome measures of physical function and radiographic progression show consistent and significant improvements in treated patients.
Tocilizumab and sarilumab have a good safety and tolerability profile. There were no major AEs of concern, and the safety profile remains stable and consistent with long-term use of either of the agents. The most commonly reported AEs include infections, neutropenia, and liver enzyme abnormalities. Transient neutropenia induced by IL-6 inhibition reflects decreased mobilization of neutrophils into the peripheral blood rather than apoptosis or phagocytosis of neutrophils. Although recruitment of neutrophils to inflammation sites may be delayed, neutrophil functions associated with host defense against infections are not significantly compromised. Elevations of liver enzymes associated with treatment with IL-6 inhibitors were mostly mild and are likely due to interference of IL-6 inhibitors with IL-6-mediated liver regeneration rather than direct toxicity. Besides, clinical improvements were noted when tocilizumab nonresponders switched to sarilumab. In addition, tocilizumab and sarilumab exhibit clinical benefits in alleviating some extra-articular manifestations of RA, such as fatigue and morning stiffness, and have positive effects on anemia and glucose metabolism.

POTENTIAL CANDIDATES FOR IL-6 INHIBITION

There are many effective therapeutic agents available for the treatment of RA. However, some agents are more suitable in certain patients than others because of the complex nature of the disease, differences in patients’ response to different agents, and the diverse clinical manifestations encountered by patients. Here, we discuss specific patient subgroups who are more likely to have additional benefit from treatment with IL-6 inhibitors.

Patients With Early RA

Interleukin 6 is implicated in the manifestation of RA from the very beginning stages. Blocking IL-6 signaling at an early stage would be beneficial and yield good prognosis. This hypothesis was tested in the FUNCTION study, which enrolled more than 1000 patients with mean disease duration of 5 months. Tocilizumab either in combination with MTX or as monotherapy was associated with higher DAS28 remission rates at 24 weeks compared with the control group (placebo + MTX). Tocilizumab treatment also retarded the structural joint damage to a significantly greater extent compared with control. In another study, more patients with early RA (diagnosis <12 months) attained sustained remission when tocilizumab was incorporated in the regimen versus placebo + MTX. In both studies, the AE profile did not differ between treatment groups. These studies showed that tocilizumab with or without MTX is more effective and has a similar safety profile, compared with MTX monotherapy in patients with early RA, and may be considered for treatment initiation in patients with newly diagnosed RA.

Patients With High Baseline IL-6

Post hoc analyses of MOBILITY and MONARCH trials revealed that patients with high levels of IL-6 at baseline (highest tertile group; serum IL-6 at 3 times upper limit of normal) had more joint damage, greater disease activity, and elevated levels of CRP than patients with low levels of IL-6 at baseline (lowest tertile group; serum IL-6 <12.5 pg/mL). Patients with elevated baseline IL-6 levels had greater clinical response to sarilumab combination therapy or monotherapy compared with placebo + MTX or adalimumab than patients with normal IL-6 levels. This suggests that patients with higher levels of IL-6 at baseline could be good candidates for IL-6 inhibitor therapy.

Patients With Anemia

Elevated levels of IL-6 are associated with the development of anemia in RA; some observations suggest that between 33% and 60% of RA patients suffer from anemia. Treatment with tocilizumab and sarilumab has been shown to increase hemoglobin levels in RA patients. Interleukin 6 inhibitors may be a good treatment option to consider RA patients with concomitant anemia.

Patients With Diabetes Mellitus

As discussed previously, treatment with tocilizumab or sarilumab has been shown to reduce hyperglycemia in RA patients. These findings suggest that IL-6 inhibitors could be considered for RA patients with concomitant diabetes mellitus.

Patients at High Risk of TB Infection

It is estimated that 25% of the world’s population carries latent TB infection, which could become active if the host’s immune system weakens. Tumor necrosis factor α inhibitors have been associated with latent TB infection reactivation. Given proper TB screening and prophylaxis, only sporadic incidents of TB were reported with long term tocilizumab sarilumab treatment. The risk of TB reactivation with tocilizumab or sarilumab treatment is low, and both tocilizumab and sarilumab may be considered a good treatment option for RA patients at risk of TB.

Patients With MTX Intolerance

The European League Against Rheumatism and ACR guidelines recommend to add bDMARDs to MTX in patients with inadequate response to MTX therapy. However, between 11% and 36% of RA patients exhibit intolerance to MTX. For these patients, bDMARDs with demonstrated efficacy in monotherapy regimens can be considered. Both tocilizumab and sarilumab have demonstrated clinical efficacy as monotherapy in RA patients, making them a suitable treatment option for MTX-intolerant patients.

CONCLUSIONS

Clinical evidence has demonstrated tocilizumab and sarilumab to be efficacious and tolerable in RA patients. They are effective in controlling RA symptoms, retarding joint damage, and inducing disease remission, either in combination with csDMARD or as monotherapy. Besides, tocilizumab and sarilumab have demonstrated additional clinical benefits in alleviating some extra-articular manifestations of RA. In addition, clinical studies revealed that certain patient subgroups, such as those with comorbidities including anemia and diabetes mellitus, those with early RA, those with high baseline IL-6 levels, those at high risk of TB infection, or those intolerant to MTX monotherapy, are possible candidates who may benefit from treatment with tocilizumab or sarilumab. Considering these advantages, tocilizumab and sarilumab are a rational choice for the treatment of RA in suitable patients. Besides clinical factors, patient’s perspectives, such as feeling of fatigue, and frequency and ease of administration are other important considerations when choosing a treatment for RA.

REFERENCES

1. Kahlenberg JM, Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin. 2011;27:11–20.
2. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl 5):v3–v11.
3. Druce KL, Cordingley L, Short V, et al. Quality of Life, Sleep and Rheumatoid Arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and...
quality of life in adults with rheumatoid arthritis. BMJ Open. 2018; 8:e018752.

4. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123–130.

5. Crowson CS, Rollefseth S, Ikdahi E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Arthritis Rheum. 2018;77:48–54.

6. Klop C, de Vries F, Bijlsma JW, et al. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis. 2016;75: 2095–2100.

7. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583–3587.

8. Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 2014;16:114.

9. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–196.

10. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328–2337.

11. Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1–25.

12. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977.

13. Rubberb-Roth A, Finek A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.

14. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 6):vi28–v36.

15. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49:15–24.

16. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.

17. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788.

18. Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2009;38:382–388.

19. Ogata A, Kato Y, Higa S, et al. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29: 258–267.

20. Straub R. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Rheumatology. 1997;36: 1298–1303.

21. Scott LJ. Sarilumab: first global approval. Drugs. 2017;77:705–712.

22. Wang G, Mu R, Xu H. Management of rheumatoid arthritis in People’s Republic of China—focus on tocilizumab and patient considerations. Int J Gen Med. 2015;8:187–194.

23. Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of ol ozukumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis. 2014;73:1607–1615.

24. Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015;67:2591–2600.

25. Holz J-B, Sargentini-Maier L, De Bruyn S, et al. OP0043 twenty-four weeks of treatment with a novel anti-IL-6 receptor Nanobody® (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase II/II study in RA. Ann Rheum Dis. 2013;72: A64–A64.

26. ACTEMRA® product monograph. Mississauga, Ontario; November 28, 2018.

27. RoActemra 20mg/mL concentrate for solution for infusion. Summary of Product Characteristics Place. Available at: https://www.medicines.org.uk/emc/product/6673/smpc.

28. ACTEMRA. Medication Guide Place. Available at: https://www.gene.com/download/pdf/actemra_prescribing.pdf.

29. RoActemra 162 mg solution for injection in pre-filled syringe. Summary of product characteristics place. Available at: https://www.medicines.org.uk/emc/product/5357/smpc.

30. Rafque A, Martin J, Blome M, et al. AB0037 evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha. Ann Rheum Dis. 2014;72(Suppl 3): A797.91–A797.97.

31. KEVZARA® product monograph, Laval, Quebec; February 14, 2018.

32. Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5: 231–242.

33. Mihaa M, Ohsugi Y, Kishimoto T. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. Open Access Rheumatol. 2011;3:19–29.

34. ACTEMRA Tocilizumab SC Place. Available at: https://www.actemra.com/ra/taking-actemra/taking-actemra-sc-injections.html. Accessed October 11, 2019.

35. Smolen JS, Beaulieu A, Rubberb-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–997.

36. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609–621.

37. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;59:2968–2980.

38. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71:198–205.

39. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.

40. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–1550.

41. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of Active Controlled Tocilizumab Monotherapy for Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (SATORI): significant reduction in
42. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.

43. Navarro G, Taroumian S, Barroso N, et al. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014;43:458–469.

44. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222–232.

45. Genovese MC, Rubbert-Roth A, Smolen JS, et al. Long-term safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40:768–780.

46. Jones G, Wallace T, Mcintosh MJ, et al. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naïve or free of methotrexate for 6 months: the AMBITION study. J Rheumatol. 2017;44:142–146.

47. Kremer JM, Blanco R, Halland AM, et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin Exp Rheumatol. 2016;34:625–633.

48. Mohan S, Michalaka M, Yorish J, et al. OP0105 long-term safety of tocilizumab from large clinical trial and postmarketing populations. Ann Rheum Dis. 2017;76:95–95.

49. Schiff MH, Kremer JM, Jahres A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:R141.

50. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424–1437.

51. Tanaka Y, Wada K, Takalashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21:79.

52. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277–290.

53. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840–847.

54. Genovese MC, van Adelsberg J, Fan C, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018;57:1423–1431.

55. Verschueren P, Emery P, van Hoogstraten H, et al. THU0215 Efficacy of Sarilumab in Patients With Rheumatoid Arthritis With and Without Previous Response to Tocilizumab. London, United Kingdom: BMJ Publishing Group Ltd and European League Against Rheumatism; 2018.

56. Genovese MC, van Adelsberg J, van Hoogstraten H, et al. O03. Clinical and radiographic outcomes after 3 years of SARILUMAB in patients with rheumatoid arthritis. Rheumatology. 2017;56(supp1_2).

57. Burmester GR, Lin Y, St John G, et al. SAT0172 long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARDs in patients with rheumatoid. Art Ther. 2018.

58. Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019;5:e000887.

59. Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford). 2019.

60. Abu-Shakra M, Zisman D, Balbir-Gurman A, et al. Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis. Isr Med Assoc J. 2018;20:239–244.

61. Townes SV, Furst DE, Thenkendorf A. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. Open Access Rheumatol. 2012;4:87–92.

62. Gossec L, Boklage S, St John G, et al. Pain is improved in around 50% of patients and fatigue in 40% of patients with rheumatoid arthritis treated with Sarilumab in the target, MOBILITY and MONARCH trials. 2018 ACR/ARHP Annual Meeting 2018.

63. Strand V, Kosinski M, Chen CL, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.

64. Strand V, Kosinski M, Graham N, et al. Impact of sarilumab on fatigue, pain, morning stiffness, productivity, and health related quality of life (HRQoL) in patients with active rheumatoid arthritis who were inadequate responders or intolerant of anti-TNF-αa therapy: results from a phase 3 study (RCT). 2015 ACR/ARHP Annual Meeting 2015.

65. Isaacs JD, Harari O, Koboldt U, et al. Effect of tocilizumab on haematological markers implies interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15:R204.

66. Burmester GR, Hagino O, Dong Q, et al. Unique changes in hemoglobin with sarilumab versus adalimumab are independent of better disease control in patients with rheumatoid arthritis (RA). 2018 ACR/ARHP Annual Meeting, October 19–24, 2018 in Chicago, IL, USA.

67. Otsuka Y, Kiyohara C, Kashiwada Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13:e0196368.

68. Genovese MC, Fleischmann R, Hagino O, et al. The effect of Sarilumab in combination with Dmards on fasting glucose and glycosylated hemoglobin in patients with rheumatoid arthritis with and without diabetes. 2017 ACR/ARHP Annual Meeting, 2017.

69. Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53:1321–1331.

70. Biggioggero M, Crotti C, Becciolini A, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther. 2019;13:57–70.

71. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early rheumatoid arthritis and inadequate responses to methotrexate or biologic DMARDs. Ann Rheum Dis. 2018;77:1081–1091.

72. Bjilsma JW, Welting PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-act-early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388:343–355.

73. Boyapati A, Msihid J, Schwartzman S, et al. 069 high baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. Rheumatology. 2019;58(Suppl 3).

74. Wilson A, Yu HT, Goodnough LT, et al. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):508–57S.
75. Fleischmann R, Lin Y, John GS, et al. SAT0125 long-term safety with Sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and Sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. *Ann Rheum Dis*. 2019;78(Suppl 2):1130–1131.

76. Baghel SS, Thakran RD, Messi C, et al. SAT0746-HPR Coffee Decreases Methotrexate Intolerance and Increases Its Compliance in Rheumatoid Arthritis (RA): A Study by Rheumatology Nurse Counsellors. BMJ Publishing Group Ltd and European League Against Rheumatism; 2018.

77. Ćalasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. *Arthritis Res Ther*. 2013;15:R217.

78. Fatimah N, Salim B, Nasim A, et al. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). *Clin Rheumatol*. 2016;35:1341–1345.

79. Teitsma XM, Marijnissen AK, Bijlsma JW, et al. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. *Arthritis Res Ther*. 2016;18:211.